Shares of Oncolytics Biotech Inc. (TSE:ONC – Get Free Report) hit a new 52-week low on Thursday . The stock traded as low as C$0.69 and last traded at C$0.74, with a volume of 74127 shares traded. The stock had previously closed at C$0.76.
Oncolytics Biotech Price Performance
The company has a debt-to-equity ratio of 11.75, a current ratio of 2.99 and a quick ratio of 8.86. The stock has a market cap of C$53.95 million, a P/E ratio of -1.95 and a beta of 1.35. The business’s fifty day moving average price is C$0.97 and its 200 day moving average price is C$1.25.
About Oncolytics Biotech
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Featured Stories
- Five stocks we like better than Oncolytics Biotech
- Health Care Stocks Explained: Why You Might Want to Invest
- Conagra Stock Could Thrive as Tariffs Hit Other Sectors
- Insider Trades May Not Tell You What You Think
- Grocery Costs and Tariffs Now Top of Mind in Everyday Conversations, New Survey Finds
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Spotify Stock Eyes Double-Digit Upside—Is Now the Time to Buy?
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
